Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152110 | 0.81 | CYP2D6 (0.34) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL659374 | 0.78 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL2151168 | 0.78 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL2152306 | 0.78 | CYP2D6 (0.36) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL222074 | 0.78 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL10512876 | 0.77 | DGAT1 (0.36) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL10549280 | 0.76 | HDAC3 (0.31) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL30265230 | 0.76 | HDAC3 (0.34) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL10549275 | 0.76 | HDAC3 (0.31) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL363977 | 0.75 | CYP2D6 (0.34) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012007409-A1 | N-SUBSTITUTED PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010235-A1 | N-SUBSTITUTED PYRROLIDINES | CHU XIN-JIE (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010235-A1 | N-SUBSTITUTED PYRROLIDINES | CHU XIN-JIE (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010235-A1 | N-SUBSTITUTED PYRROLIDINES | CHU XIN-JIE (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010235-A1 | N-SUBSTITUTED PYRROLIDINES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD1, TP53 | HDAC3 2282/4885HDAC1 1269/4885HDAC2 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.